Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1173908 | 0.95 | CPB2 (0.33) | CPB2 | |
| SCHEMBL23794918 | 0.95 | CPB2 (0.33) | CPB2 | |
| SCHEMBL30943445 | 0.95 | CPB2 (0.33) | CPB2 | |
| SCHEMBL23195986 | 0.94 | CPB2 (0.35) | CPB2 | |
| SCHEMBL11230136 | 0.88 | — | — | |
| SCHEMBL21891821 | 0.87 | — | — | |
| SCHEMBL21175596 | 0.85 | — | — | |
| SCHEMBL21319497 | 0.85 | NAAA (0.39) | CPB2 | |
| SCHEMBL14411072 | 0.85 | NAAA (0.32) | CPB2 | |
| SCHEMBL3417815 | 0.85 | CA2 (0.38) | CPB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11352319-B2 | Method for producing carbamate and method for producing isocyanate | ASAHI KASEI KABUSHIKI KAISHA (JP) | 2022-06-07 | — | — | US | disclosed |
| US-11118001-B2 | Isocyanate composition, method for producing isocyanate composition, and method for producing isocyanate polymer | ASAHI KASEI KABUSHIKI KAISHA (JP) | 2021-09-14 | — | — | US | disclosed |
| US-11078321-B2 | — | — | 2021-08-03 | — | — | US | disclosed |
| US-20210179548-A1 | METHOD FOR PRODUCING CARBAMATE AND METHOD FOR PRODUCING ISOCYANATE | ASAHI KASEI KABUSHIKI KAISHA (JP) | 2021-06-17 | — | — | US | disclosed |
| US-10968168-B2 | Isocyanate production method | ASAHI KASEI KABUSHIKI KAISHA (JP) | 2021-04-06 | — | — | US | disclosed |
| EP-3626705-B1 | ISOCYANATE PRODUCTION METHOD | ASAHI CHEMICAL IND (JP) | 2021-03-24 | — | — | EP | disclosed |
| US-20200115327-A1 | ISOCYANATE PRODUCTION METHOD | ASAHI KASEI KABUSHIKI KAISHA (JP) | 2020-04-16 | — | — | US | disclosed |
| US-20200048403-A1 | ISOCYANATE COMPOSITION, METHOD FOR PRODUCING ISOCYANATE COMPOSITION, AND METHOD FOR PRODUCING ISOCYANATE POLYMER | ASAHI KASEI KABUSHIKI KAISHA (JP) | 2020-02-13 | — | — | US | disclosed |
| US-4350791-A | Vinylpyrrolidone polymers, their preparation, their use in the preparation of plasma substitutes, and the substitutes thus obtained | BASF AKTIENGESELLSCHAFT (DE) | 1982-09-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11352319-B2 | Method for producing carbamate and method for producing isocyanate | CPS1, CA7, CA4 | CPB2 898/4885 |
| US-11078321-B2 | — | IDH3A, IPO4, F12 | CPB2 4000/4885 |
| US-20200115327-A1 | ISOCYANATE PRODUCTION METHOD | IDH3A, ALKBH3, CPS1 | CPB2 744/4885 |
| US-20210179548-A1 | METHOD FOR PRODUCING CARBAMATE AND METHOD FOR PRODUCING ISOCYANATE | CPS1, CA7, CA4 | CPB2 898/4885 |
| US-10968168-B2 | Isocyanate production method | IDH3A, ALKBH3, CPS1 | CPB2 744/4885 |
| US-11118001-B2 | Isocyanate composition, method for producing isocyanate composition, and method for producing isocyanate polymer | IDH3A, IPO4, IDH3B | CPB2 3856/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.